Anti-PD-1/Anti-TIM-3 Bispecific Antibody LB1410 clinical trials
Also written LB1410.
Its developmentBy L & L Bio Co., Ltd., Ningbo, China, step by step3 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-PD-1/Anti-TIM-3 Bispecific Antibody LB1410 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-PD-1/Anti-TIM-3 Bispecific Antibody LB1410 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LB1410
- 3
Studies by the year they started
3 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
L & L Bio Co., Ltd., Ningbo, China (3)
Often tested with
Tested in the same studies.
LB4330 (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Anti-PD-1/Anti-TIM-3 Bispecific Antibody LB1410.
- Dec 2026A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid TumorsPhase 1/2 · L & L Bio Co., Ltd., Ningbo, China
- Dec 2026A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma(Keyplus-001)Phase 1 · L & L Bio Co., Ltd., Ningbo, China
Studies
Open first, then newest update. How each study uses Anti-PD-1/Anti-TIM-3 Bispecific Antibody LB1410 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical CancerNot yet recruitingPhase 2/3L & L Bio Co., Ltd., Ningbo, ChinaNCT07177716Written as LB1410How we know
- A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid TumorsRecruitingPhase 1/2L & L Bio Co., Ltd., Ningbo, ChinaNCT06468358Written as LB1410How we know
- A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma(Keyplus-001)RecruitingPhase 1L & L Bio Co., Ltd., Ningbo, ChinaNCT05357651Written as LB1410How we know